Dr. Eric Gregory Abkian, MD

Dr. Abkian practices at Providence Cedars-Sinai Tarzana Medical Center in Tarzana, California, part of Providence Health & Services.

Dr. Abkian's NPI, 1750841920, was assigned on March 22, 2019. Dr. Abkian holds California license A193251.

Dr. Abkian's primary practice is Providence Cedars-Sinai Tarzana Medical Center, at 18321 Clark Street, Tarzana, CA 91356 in Los Angeles County. The practice phone is (818) 881-0800.

Dr. Abkian's primary practice is Providence Cedars-Sinai Tarzana Medical Center in Tarzana, California, part of Providence Health & Services. Dr. Abkian is also affiliated with Dignity Health - St. John's Regional Medical Center. The medical group on file is Cedars-Sinai Medical Group. Dmand AI also links Dr. Abkian to 3 more medical groups, 2 group practices and clinics and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Abkian practices, 5 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Abkian's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dmand AI has Dr. Abkian's licenses on file in 2 states: California and Florida.

CMS data shows 1,000 Medicare services from Dr. Abkian across 6 procedure codes in 2024, for 461 Medicare patients. Medicare paid $79,943 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 461 Medicare patients who saw Dr. Abkian in 2024. The largest group is 75 to 84, with 175 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 2.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Abkian's median patient age at 67, with 46% women.

In 2024, Dr. Abkian wrote 255 Medicare Part D claims for 141 patients. 85% of them were for generic drugs. CMS names the drug for 14 of them, across 1 drug with 11 or more claims each, at $8,522 in total drug cost. In 2023, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Abkian for performance year 2024, reported individually. Dr. Abkian accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 9 general payments to Dr. Abkian from 6 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 100% of the total. Paratek Pharmaceuticals, Inc. paid the most, $105.